We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
India-based Bharat Biotech’s COVID-19 vaccine, Covaxin (BBV152), was just 50 percent effective in preventing infections among hospital employees in India who received the recommended two doses. Read More
Did former FDA Commissioner Stephen Hahn cave to political pressure from the Trump Administration in authorizing hydroxychloroquine and convalescent plasma as treatments for COVID-19 even though there was scant evidence of their efficacy? Read More
The two-dose Pfizer-BioNTech COVID-19 vaccine regimen was 100 percent effective in preventing disease in children aged 12-15 years, the companies reported. Read More
Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported the decision. Read More
AstraZeneca’s one-time dual-antibody injection cut the risk of symptomatic COVID-19 by up to 83 percent and the risk of severe disease by 88 percent in two studies of high-risk patients. Read More
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its experimental COVID-19 antiviral, Paxlovid (PF-07321332; ritonavir), to be delivered later this year and into 2022. Read More
The companies said they will supply an unspecified number of doses by mid-December and that the government has an option to purchase additional doses through March 2022. Read More
Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalization or death. Read More
Faced with defending its COVID-19 vaccine in the face of troubling side effects, Moderna held a conference call late last week to discuss the risk of heart inflammation in young people. Read More
The European Medicines Agency (EMA) has given the thumbs up to two COVID-19 antibody therapies from Regeneron-Roche and Celltrion Healthcare, paving the way for imminent approval by the European Commission. Read More
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects. Read More